1. Long-term controlled growth factor release using layer-by-layer assembly for the development of In vivo tissue-engineered blood vessels
- Author
-
Damanik, F.F.R., Rothuizen, C.T., Lalai, R., Khoenkhoen, S., Blitterswijk, C. van, Rotmans, J.I., Moroni, L., CTR, and RS: MERLN - Complex Tissue Regeneration (CTR)
- Subjects
in vivo bioreactor ,SMOOTH-MUSCLE-CELLS ,layer-by-layer ,FACTOR-BETA ,RAT AORTA ,in situ tissue engineering ,vascular access ,TGF-BETA ,FACTOR DELIVERY ,growth factor release ,REGENERATION ,General Materials Science ,MESSENGER-RNA ,ELASTIN ,MYOFIBROBLASTS ,tissue-engineered blood vessels ,GENE-EXPRESSION ,biomaterials - Abstract
The development of a well-designed tissue-engineered blood vessel (TEBV) still remains a challenge. In recent years, approaches in which the host response to implanted biomaterials is used to generate vascular constructs within the patient's body have gained increasing interest. The delivery of growth factors to these in situ-engineered vascular grafts might enhance myofibroblast recruitment and the secretion of essential extracellular matrix proteins, thereby optimizing their functional properties. Layer-by-layer (LbL) coating has emerged as an innovative technology for the controlled delivery of growth factors in tissue engineering applications. In this study, we combined the use of surface-etched polymeric rods with LbL coatings to control the delivery of TGF-beta 1, PDGF-BB, and IGF-1 and steer the foreign body response toward the formation of a functional vascular graft. Results showed that the regenerated tissue is composed of elastin, glycosaminoglycans, and circumferentially oriented collagen fibers, without calcification or systemic spill of the released growth factors. Functional controlled delivery was observed, whereas myofibroblast-rich tissue capsules were formed with enhanced collagen and elastin syntheses using TGF-beta 1 and TGF-beta 1/PDGF-BB releasing rods, when compared to control rods that were solely surface-engineered by chloroform etching. By combining our optimized LbL method and surface-engineered rods in an in vivo bioreactor approach, we could regulate the fate and ECM composition of in situ-engineered vascular grafts to create a successful in vivo vascular tissue-engineered replacement.
- Published
- 2022